Wuhan Healthgen Biotechnology Corporation et al v. ExpressTec LLC et al

IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF KANSAS
WUHAN HEALTHGEN BIOTECHNOLOGY 	)
CORPORATION, et al., 	)
)
Plaintiffs, 	) 	CIVIL ACTION
)
v. 	) 	No. 24-4089-KHV
)
EXPRESSTEC LLC, et al., 	)
)
Defendants. 	)
____________________________________________)
)
VENTRIA BIOSCIENCE INC., 	)
)
Plaintiff, 	) 	CIVIL ACTION
)
v. 	) 	No. 21-4008-KHV
)
WUHAN HEALTHGEN BIOTECHNOLOGY 	)
CORP., 	)
)
Defendant. 	)
____________________________________________)
MEMORANDUM AND ORDER
This matter is before the Court on Invitria’s Unopposed Motion To Redact Healthgen’s
Summary-Judgment (ECF 307) And Daubert (ECF 309) Responses And To Redact And Seal
Exhibits To Same (Doc. #319) filed January 18, 2026. For reasons stated below, the Court sustains
the motion in part.
Federal courts have long recognized a common-law right of access to judicial records.
Mann v. Boatright, 477 F.3d 1140, 1149 (10th Cir. 2007). This right stems from the fundamental
public interest in understanding disputes that parties present to a public forum for resolution. See
Nixon v. Warner Commc’ns, 435 U.S. 589, 599 (1978); Crystal Grower’s Corp. v. Dobbins, 616
F.2d 458, 461 (10th Cir. 1980). 	In determining whether documents should be sealed, the Court
Case 5:24-cv-04089-KHV Document 332 Filed 01/27/26 Page 1 of 4

-2-
weighs the public interest, which it presumes is paramount, against the interests advanced by the
parties. Helm v. Kansas, 656 F.3d 1277, 1292 (10th Cir. 2011). The party seeking to overcome
the presumption of public access must show that some significant interest which favors non-
disclosure outweighs the public interest in access to court proceedings and documents. 	Colony
Ins. Co. v. Burke, 698 F.3d 1222, 1241 (10th Cir. 2012). To do so, the party must articulate a real
and substantial interest that justifies depriving the public of access to the records that inform the
Court’s decision-making process. 	Id.; see also Gulf Oil Co. v. Bernard, 452 U.S. 89, 102 n.16
(1981) (moving party must submit particular and specific facts, not merely “stereotyped and
conclusory statements”). The Court must rely on specific, rather than general, information when
deciding to seal. See United States v. Bacon, 950 F.3d 1286, 1294 (10th Cir. 2020).
I. 	Defendants’ Manufacturing Processes
Defendants ask the Court for leave to redact their memoranda and exhibits which reference
confidential and proprietary manufacturing processes which they use to extract and purify
recombinant human serum albumin (“rHSA”) products and the composition of extraction buffers
that InVitria uses to extract crude rHSA from rice. Plaintiffs do not oppose defendants’ motion.
Defendants have shown that due to their security measures, competitors could not otherwise access
their processes and compositions. 	Defendants have also specifically explained how disclosure
would harm their business and financial interests, i.e. potential competitors could use the
information to replicate defendants’ methods for extracting and purifying rHSA from rice.
Defendants propose redactions which are narrowly tailored to their asserted confidentiality
interests. On balance, defendants have shown that their interests outweigh the public interest in
access to the unredacted materials that form part of the basis of this lawsuit. See Colony Ins., 698
F.3d at 1241. The Court therefore sustains defendants’ motion to redact materials which reference
Case 5:24-cv-04089-KHV Document 332 Filed 01/27/26 Page 2 of 4

-3-
confidential and proprietary manufacturing processes which they use to extract and purify rHSA
products and the composition of extraction buffers that InVitria uses to extract crude rHSA from
rice.
II. 	Defendants’ Sales And Pricing Data
Defendants ask the Court to redact Exhibit 6 and seal Exhibit 9 to their summary judgment
response, which disclose non-public sales and pricing information. 	The Court previously
overruled defendants’ requests to seal their sales and revenue documents, which included “invoice
amounts from specific InVitria customers” and “information such as InVitria’s internal pricing
structure, manufacturing plans, internal costs of production, and other confidential information.”
Defendants’ Unopposed Motion To Seal Exhibits R, K, J, Q, M, And H To Plaintiffs’ Motion To
Compel Production Of Documents (Doc. #213) filed July 25, 2025 at 5; see Memorandum And
Order (Doc. #223) at 4–5. 	As with defendants’ prior motion, defendants have not specifically
explained how disclosure of sales and pricing information would harm them or that their
competitors could not otherwise obtain this information. On this record, defendants have not met
the heavy burden to articulate a real and substantial interest which justifies depriving the public
access to the records which inform the Court’s decision process. 	See Colony Ins., 698 F.3d at
1242 (denying motions to seal where parties did not submit specific argument or facts indicating
why 	confidentiality 	of 	settlement 	agreements 	outweighs 	presumption 	of 	public 	access).
Accordingly, the Court overrules defendants’ motion to redact Exhibit 6 and seal Exhibit 9.
IT 	IS 	THEREFORE 	ORDERED 	that 	Invitria’s 	Unopposed 	Motion 	To 	Redact
Healthgen’s Summary-Judgment (ECF 307) And Daubert (ECF 309) Responses And To Redact
And Seal Exhibits To Same (Doc. #319) filed January 18, 2026 is SUSTAINED as to materials
which reference confidential and proprietary manufacturing processes which they use to
Case 5:24-cv-04089-KHV Document 332 Filed 01/27/26 Page 3 of 4

-4-
extract and purify rHSA products and the composition of extraction buffers that InVitria
uses to extract crude rHSA from rice. 	On or before January 29, 2026, counsel shall file
redacted copies of the following documents: Healthgen’s Response To Invitria’s Motion To
Exclude Testimony Of Dr. Aaron Sato (Doc. #307) filed January 9, 2026; Exhibits 1, 2 and 4
(Doc. ##307-2, 307-3 and 307-5) to Healthgen’s Response To Invitria’s Motion To Exclude
Testimony Of Dr. Aaron Sato (Doc. #307) filed January 9, 2026; Healthgen’s Opposition To
Invitria’s Motion For Summary Judgment (Doc. #309) filed January 9, 2026; and Exhibits 1,
3, 5, 11 and 12 (Doc. ##309-2, 309-4, 309-6, 309-9 and 309-10) to Healthgen’s Opposition To
Invitria’s Motion For Summary Judgment (Doc. #309). The process of sealing and redaction
and re-filing shall not operate to extend any deadlines for responses to the documents in
question. All deadlines shall be calculated from the date of the original filing.
IT IS FURTHER ORDERED that the Clerk shall unseal the following provisionally
sealed documents (Doc. ##307-4, 309-3, 309-5, 309-7 and 309-8).
Dated this 27th day of January, 2026 at Kansas City, Kansas.
s/ Kathryn H. Vratil
KATHRYN H. VRATIL
United States District Judge
Case 5:24-cv-04089-KHV Document 332 Filed 01/27/26 Page 4 of 4